TKI precisely target the tyrosine kinase encoded by the BCR-ABL fusion gene, effectively blocking the proliferation signaling pathway in CML cells to achieve deep and durable disease control. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.